Alchemab Therapeutics
alchemab.com Cambridge UK company Series A
- Headquarters
- Cambridge
- Sector
- healthcare
- Stage
- Series A
- Incorporated
- 2019
What does Alchemab Therapeutics do?
Alchemab studies people who should have got seriously ill and did not, sequencing their immune systems to find the antibodies protecting them. It inverts the usual approach of designing an antibody and hoping the body tolerates it.
How does Alchemab Therapeutics work?
Sequences the immune repertoires of people who resisted a disease and looks for antibodies shared across them, inverting the usual design-and-test approach.
What does Alchemab Therapeutics offer?
Antibody therapeutics for neurodegeneration and cancer, developed with partners.
Alchemab Therapeutics discovers target antigens and antibodies by analysing the immune repertoires of resilient individuals who naturally resist severe diseases. The company uses deep sequencing and machine learning to isolate antibody sequences shared among protected cohorts in neurodegenerative diseases and cancer. Founded in Cambridge in 2019, Alchemab raised an $82m Series A in 2021.
Who runs Alchemab Therapeutics?
Alchemab Therapeutics has 8 currently appointed directors.
- Malcolm Derek Gates
- Catherine Elizabeth, Dame Bingham
- Carmine Daniel, Dr. Circelli
- Jenna Hebert
- Kevin Lee
- Andrew Paul, Dr May
- Jane Katharine Osbourn
- Douglas, Dr Treco
Currently appointed officers only, from the Companies House register. Directors who have resigned are excluded — naming someone who left as running the company is worse than naming nobody.
Where is Alchemab Therapeutics based?
Alchemab Therapeutics is headquartered in Cambridge, outside London. It was incorporated in 2019. Other AI companies in Cambridge →
Why does Alchemab Therapeutics matter to a UK operator?
Studies people who should have got seriously ill and did not. An inversion of standard drug discovery that is easy to explain and hard to execute.
Company record
Registered as ALCHEMAB THERAPEUTICS LTD, company 12156844, a private limited company, incorporated on 14 August 2019. Registered office: East Side Office 1.02, Kings Cross, London, United Kingdom, N1C 4AX. SIC 72110 - Research and experimental development on biotechnology.
Looked up on the register. Of the first 83 numbers supplied to this directory, 12 belonged to entirely different businesses.
What else is Torus tracking near Alchemab Therapeutics?
6 other UK companies working in healthcare:
6 other AI companies headquartered in Cambridge: